Avant Sciences

Executive Summary

Avant Sciences is a pre-clinical stage diagnostics and AI/ML company focused on retinal disease and ocular inflammation. Founded in 2018 and based in San Diego, the company is led by Dr. Avnish Deobhakta, a faculty member at Mount Sinai's New York Eye and Ear Infirmary and an expert in vitreoretinal surgery. Leveraging AI and machine learning, Avant aims to develop novel therapeutics and devices for diagnosing and treating retinal conditions. While the company has not yet disclosed specific pipeline details or funding rounds, its strong scientific foundation and focus on high-need ophthalmic areas position it for potential growth. However, as a pre-clinical entity, it faces significant development and regulatory hurdles. The market for retinal disease diagnostics is expanding, driven by aging populations and increasing prevalence of conditions like diabetic retinopathy and age-related macular degeneration, offering a promising backdrop for Avant's technologies.

Upcoming Catalysts (preview)

• TBDSeries A Financing Round40% success
• TBDPreclinical Data Release for Lead Candidate50% success
• TBDStrategic Partnership with Ophthalmology Device Company30% success